The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): Protocol of a randomized, double-blind, placebo-controlled multicenter trial

Jiann Shing Jeng; Yu Sun; Jiunn Tay Lee; Ruey Tay Lin; Chih Hung Chen; Helen L. Po; Huey Juan Lin; Chung Hsiang Liu; Ming Hui Sun; Mu Chien Sun; Chang Ming Chern; Li Ming Lien; Hou Chang Chiu; Han Hwa Hu; Hung Yi Chiou; Sien Tsong Chen; Henry Ma; Chung Y. Hsu; SPAD Study Investigators

doi:10.1111/ijs.12384

The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): Protocol of a randomized, double-blind, placebo-controlled multicenter trial

Jiann Shing Jeng, Yu Sun, Jiunn Tay Lee, Ruey Tay Lin, Chih Hung Chen, Helen L. Po, Huey Juan Lin, Chung Hsiang Liu, Ming Hui Sun, Mu Chien Sun, Chang Ming Chern, Li Ming Lien, Hou Chang Chiu, Han Hwa Hu, Hung Yi Chiou, Sien Tsong Chen, Henry Ma, Chung Y. Hsu, SPAD Study Investigators

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

Rationale: It is not uncommon for patients with ischemic stroke to have peripheral arterial disease (PAD). Patients with polyvascular diseases carry greater burden of atherosclerosis and higher risks of developing vascular events and death. More effective regimens, such as dual antiplatelet agents, may be more effective for controlling progression of atherosclerosis in secondary prevention. Aim: This study aims to evaluate whether cilostazol plus aspirin is more efficacious than aspirin alone for preventing progression of atherosclerosis in patients with ischemic stroke or transient ischemic attack (TIA) who also have peripheral arterial disease. Design: The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients with Peripheral Arterial Disease (SPAD) study is a randomized double-blinded placebo-controlled trial. Patients with previous ischemic stroke or TIA who had been taking aspirin (100mg per day), aged 50 years or older, with PAD in the lower limbs based on ankle-brachial index (ABI)

Original language	English
Pages (from-to)	123-127
Number of pages	5
Journal	International Journal of Stroke
Volume	10
Issue number	1
DOIs	https://doi.org/10.1111/ijs.12384
Publication status	Published - Jan 1 2015

Keywords

Ankle-brachial index
Aspirin
Cilostazol
Intima-media thickness
Ischemic stroke
Peripheral arterial disease

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1111/ijs.12384

Cite this

Jeng, J. S., Sun, Y., Lee, J. T., Lin, R. T., Chen, C. H., Po, H. L., Lin, H. J., Liu, C. H., Sun, M. H., Sun, M. C., Chern, C. M., Lien, L. M., Chiu, H. C., Hu, H. H., Chiou, H. Y., Chen, S. T., Ma, H., Hsu, C. Y., & SPAD Study Investigators (2015). The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): Protocol of a randomized, double-blind, placebo-controlled multicenter trial. International Journal of Stroke, 10(1), 123-127. https://doi.org/10.1111/ijs.12384

The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): Protocol of a randomized, double-blind, placebo-controlled multicenter trial. / Jeng, Jiann Shing; Sun, Yu; Lee, Jiunn Tay et al.
In: International Journal of Stroke, Vol. 10, No. 1, 01.01.2015, p. 123-127.

Research output: Contribution to journal › Article › peer-review

Jeng, JS, Sun, Y, Lee, JT, Lin, RT, Chen, CH, Po, HL, Lin, HJ, Liu, CH, Sun, MH, Sun, MC, Chern, CM, Lien, LM, Chiu, HC, Hu, HH , Chiou, HY, Chen, ST, Ma, H, Hsu, CY & SPAD Study Investigators 2015, 'The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): Protocol of a randomized, double-blind, placebo-controlled multicenter trial', International Journal of Stroke, vol. 10, no. 1, pp. 123-127. https://doi.org/10.1111/ijs.12384

@article{6d0f5a0fdc704bd797ec790f61f9ea93,

title = "The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): Protocol of a randomized, double-blind, placebo-controlled multicenter trial",

abstract = "Rationale: It is not uncommon for patients with ischemic stroke to have peripheral arterial disease (PAD). Patients with polyvascular diseases carry greater burden of atherosclerosis and higher risks of developing vascular events and death. More effective regimens, such as dual antiplatelet agents, may be more effective for controlling progression of atherosclerosis in secondary prevention. Aim: This study aims to evaluate whether cilostazol plus aspirin is more efficacious than aspirin alone for preventing progression of atherosclerosis in patients with ischemic stroke or transient ischemic attack (TIA) who also have peripheral arterial disease. Design: The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients with Peripheral Arterial Disease (SPAD) study is a randomized double-blinded placebo-controlled trial. Patients with previous ischemic stroke or TIA who had been taking aspirin (100mg per day), aged 50 years or older, with PAD in the lower limbs based on ankle-brachial index (ABI) ",

keywords = "Ankle-brachial index, Aspirin, Cilostazol, Intima-media thickness, Ischemic stroke, Peripheral arterial disease",

author = "Jeng, {Jiann Shing} and Yu Sun and Lee, {Jiunn Tay} and Lin, {Ruey Tay} and Chen, {Chih Hung} and Po, {Helen L.} and Lin, {Huey Juan} and Liu, {Chung Hsiang} and Sun, {Ming Hui} and Sun, {Mu Chien} and Chern, {Chang Ming} and Lien, {Li Ming} and Chiu, {Hou Chang} and Hu, {Han Hwa} and Chiou, {Hung Yi} and Chen, {Sien Tsong} and Henry Ma and Hsu, {Chung Y.} and {SPAD Study Investigators}",

note = "Publisher Copyright: {\textcopyright} 2014 World Stroke Organization.",

year = "2015",

month = jan,

day = "1",

doi = "10.1111/ijs.12384",

language = "English",

volume = "10",

pages = "123--127",

journal = "International Journal of Stroke",

issn = "1747-4930",

publisher = "SAGE Publications Ltd",

number = "1",

}

TY - JOUR

T1 - The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD)

T2 - Protocol of a randomized, double-blind, placebo-controlled multicenter trial

AU - Jeng, Jiann Shing

AU - Sun, Yu

AU - Lee, Jiunn Tay

AU - Lin, Ruey Tay

AU - Chen, Chih Hung

AU - Po, Helen L.

AU - Lin, Huey Juan

AU - Liu, Chung Hsiang

AU - Sun, Ming Hui

AU - Sun, Mu Chien

AU - Chern, Chang Ming

AU - Lien, Li Ming

AU - Chiu, Hou Chang

AU - Hu, Han Hwa

AU - Chiou, Hung Yi

AU - Chen, Sien Tsong

AU - Ma, Henry

AU - Hsu, Chung Y.

AU - SPAD Study Investigators

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Rationale: It is not uncommon for patients with ischemic stroke to have peripheral arterial disease (PAD). Patients with polyvascular diseases carry greater burden of atherosclerosis and higher risks of developing vascular events and death. More effective regimens, such as dual antiplatelet agents, may be more effective for controlling progression of atherosclerosis in secondary prevention. Aim: This study aims to evaluate whether cilostazol plus aspirin is more efficacious than aspirin alone for preventing progression of atherosclerosis in patients with ischemic stroke or transient ischemic attack (TIA) who also have peripheral arterial disease. Design: The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients with Peripheral Arterial Disease (SPAD) study is a randomized double-blinded placebo-controlled trial. Patients with previous ischemic stroke or TIA who had been taking aspirin (100mg per day), aged 50 years or older, with PAD in the lower limbs based on ankle-brachial index (ABI)

AB - Rationale: It is not uncommon for patients with ischemic stroke to have peripheral arterial disease (PAD). Patients with polyvascular diseases carry greater burden of atherosclerosis and higher risks of developing vascular events and death. More effective regimens, such as dual antiplatelet agents, may be more effective for controlling progression of atherosclerosis in secondary prevention. Aim: This study aims to evaluate whether cilostazol plus aspirin is more efficacious than aspirin alone for preventing progression of atherosclerosis in patients with ischemic stroke or transient ischemic attack (TIA) who also have peripheral arterial disease. Design: The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients with Peripheral Arterial Disease (SPAD) study is a randomized double-blinded placebo-controlled trial. Patients with previous ischemic stroke or TIA who had been taking aspirin (100mg per day), aged 50 years or older, with PAD in the lower limbs based on ankle-brachial index (ABI)

KW - Ankle-brachial index

KW - Aspirin

KW - Cilostazol

KW - Intima-media thickness

KW - Ischemic stroke

KW - Peripheral arterial disease

UR - http://www.scopus.com/inward/record.url?scp=84916238893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916238893&partnerID=8YFLogxK

U2 - 10.1111/ijs.12384

DO - 10.1111/ijs.12384

M3 - Article

C2 - 25394855

AN - SCOPUS:84916238893

SN - 1747-4930

VL - 10

SP - 123

EP - 127

JO - International Journal of Stroke

JF - International Journal of Stroke

IS - 1

ER -

The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): Protocol of a randomized, double-blind, placebo-controlled multicenter trial

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this